Is acemini effective in the treatment of chronic myelogenous leukemia?

Aximini is effective in the treatment of chronic myelogenous leukemia. Aceminib is a STAMPinhibitor that specifically targets the ABL1myristoyl pocket. It is different from traditional tyrosine kinase inhibitors (TKI), which typically bind to BCR-ABL1’s ATP binding site. Aceminib can effectively alleviate the resistance of TKIs to CML and thus improve the efficacy.

Aximini is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ Patients with the chronic phase (CP) of CML), especially those who have previously received two or more tyrosine kinase inhibitors (TKI), and patients with the T315I mutation.

Aximinib was compared with bosutinib in a global, multicenter Phase 3 randomized controlled trial (ASCEMBL study). The results of the study showed that the rate of major molecular response (MMR) at 24 weeks was significantly higher in patients treated with aceminib than in the control group. This demonstrates the effectiveness of aceminib in treating refractory CML patients.

In addition, aceminib has shown good safety and tolerability, which is important for patients on long-term treatment.

Although aceminib has achieved remarkable results in the treatment ofCML, like other anti-cancer drugs, it also suffers from drug resistance problems. This is mainly due to new mutations in the target structure and bypass activation pathways in tumor cells. However, the problem of resistance to aximinib can be addressed through strategies such as strengthening surveillance, rational use of other anti-tumor drugs, and development of new targeted drugs.